Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study

Basit Öğe Kaydı
dc.contributor.authorDossenbach, Martin
dc.contributor.authorDyachkova, Yulia
dc.contributor.authorPirildar, Sebnem
dc.contributor.authorAnders, Martin
dc.contributor.authorKhalil, Afaf
dc.contributor.authorAraszkiewicz, Aleksander
dc.contributor.authorShakhnovich, Tamara
dc.contributor.authorAkram, Aly
dc.contributor.authorPecenak, Jan
dc.contributor.authorMcBride, Margaret
dc.contributor.authorTreuer, Tamas
dc.date.accessioned2019-10-27T19:18:20Z
dc.date.available2019-10-27T19:18:20Z
dc.date.issued2006
dc.departmentEge Üniversitesien_US
dc.description.abstractPurpose. - Sexual dysfunction in patients with schizophrenia can reduce quality of life and treatment compliance. This report will compare the effects of selected atypical and typical antipsychotics on sexual function in a large, international population of outpatients with schizophrenia who were treated over 1 year. Subjects and methods. - Outpatients with schizophrenia, who initiated or changed antipsychotic treatment, and entered this 3-year, prospective, observational study were classified according to the monotherapy prescribed at baseline: olanzapine (N = 2638), risperidone (N = 860), quetiapine (Al = 142) or haloperidol (N = 188). Results. - Based on patient perception, the odds of experiencing sexual dysfunction during I year of therapy was significantly lower for patients treated with olanzapine and quetiapine when compared to patients who received risperidone or haloperidol (all P < 0.001). Females on olanzapine (14%) or quetiapine (8%) experienced a lower rate of menstrual irregularities, compared to females on risperidone (23%) or haloperidol (29%). Significant discordance was evident between patient reports and psychiatrist perception of sexual dysfunction, with psychiatrists underestimating sexual dysfunction (P < 0.001). Conclusion. - These findings indicate clinically relevant differences exist in the sexual side effect profiles of these selected antipsychotics. These factors should be considered when selecting the most appropriate treatment for outpatients with schizophrenia. ((c) 2006 Elsevier SAS. All rights reserved.en_US
dc.identifier.doi10.1016/j.eurpsy.2005.12.005en_US
dc.identifier.endpage258en_US
dc.identifier.issn0924-9338
dc.identifier.issn1778-3585
dc.identifier.issue4en_US
dc.identifier.pmid16530390en_US
dc.identifier.startpage251en_US
dc.identifier.urihttps://doi.org/10.1016/j.eurpsy.2005.12.005
dc.identifier.urihttps://hdl.handle.net/11454/38560
dc.identifier.volume21en_US
dc.identifier.wosWOS:000239032900007en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier France-Editions Scientifiques Medicales Elsevieren_US
dc.relation.ispartofEuropean Psychiatryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectschizophreniaen_US
dc.subjectsexual dysfunctionen_US
dc.subjecthyperprolactinemiaen_US
dc.subjectantipsychotic agentsen_US
dc.titleEffects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu